Trial record 2 of 6 for:    Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01178216
Recruitment Status : Completed
First Posted : August 10, 2010
Last Update Posted : December 27, 2017
Genentech, Inc.
Information provided by (Responsible Party):
Stanley Jordan, MD, Cedars-Sinai Medical Center

Brief Summary:
This single center, Phase I/II, exploratory study has been modified to a safety/efficacy study providing all patients with IVIG and Rituximab. The trial will examine the safety and efficacy of human polyclonal IVIG 10%, when given at [2.0 gm/kgx2], + Rituximab 1gm to reduce donor-specific antibodies (DSA) to a level that is permissive for transplantation in 75 subjects (adults only ages >18 yrs) who are highly-HLA sensitized and are awaiting deceased donor kidney transplant. Once transplant offers are entertained, a donor-specific crossmatch will be performed. If acceptable crossmatches and DSA levels are seen, the patients will proceed to DD transplantation. Patients receiving transplants will receive an additional dose of IVIG at transplantation (within 10 days) and will receive additional doses of Rituximab 1g at 3M post transplant if DSA levels remain or become positive at 6M if de novo DSA occur. Patients who are desensitized and not transplanted at 9M after desensitization will have completed the study and can be treated as best judged by their physician.

Condition or disease Intervention/treatment Phase
End Stage Renal Disease Biological: Rituxan Phase 1 Phase 2

Detailed Description:

Organ transplantation offers the only hope for a normal life for patients with end-stage renal disease on dialysis. For patients with antibodies to human leukocyte antigens (HLA), transplantation is extremely difficult or impossible since pre-formed antibodies will cause severe rejection and loss of transplanted organs. Intravenous gamma globulin (IVIG) can reduce or eliminate these antibodies in most patients and allow for successful transplantation. This breakthrough has allowed patients previously considered not transplantable to receive life-saving transplants. However, IVIG alone does not always eradicate the anti-HLA antibodies to a degree that will allow transplantation.

In this study, the investigators propose additional treatment with rituximab, a humanized antibody directed at the CD20 antigen that is present on most B-cells. Both IVIG and rituximab are approved by the U.S. Food and Drug Administration (FDA) for numerous immunologic disorders and Non-Hodgkin's lymphoma, respectively. However, neither is approved by the FDA for desensitization of highly-HLA sensitized transplant patients. A previously conducted pilot study demonstrated IVIG + Rituximab can fill an important gap in the current therapeutic approach for management of highly sensitized patients and may become the standard therapy.

Update: Study updated after observation that subjects transplanted after desensitization with IVIG alone experienced higher rates of antibody rejection and graft loss. The primary objective of this revised protocol will be to examine the safety and efficacy of IVIG 2gm/kg (maximum 140g) given on day#0 & day #30 plus Rituximab 1gm given on day #15. Transplanted patients will receive additional doses of Rituximab 1gm at 3 months post-transplant if donor specific antibody (DSA) levels remain or become positive or at 6M if de novo DSA occur. All transplanted patients who remain DSA negative, will not receive additional Rituximab. All transplanted patients will have a protocol biopsy at transplant and 12 months. All subjects will complete 5 visits in the pre-transplant phase of the study. Patients who are transplanted will have additional 5 post-transplant visits. The following are research-related procedures:

  1. Rituximab infusion.
  2. Kidney allograft biopsies (Intra-op, 12 months post-transplant)
  3. Rituximab level, HACA levels
  4. Immunologic biomarkers (CD19+, CD38+, CD27+)

Although the investigator commonly uses both treatment regimens at Cedars-Sinai Medical Center, only the IVIG treatment is considered to be standard of care for highly HLA-sensitized patients. The investigational component of this study is the addition of the rituximab. Currently the study has been amended to a safety and efficacy study focusing on decreasing HLA antibodies pre-transplant and minimizing DSA post-transplant.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of Immune Globulin Intravenous (Human), 10% (IVIG), Plus Rituximab as Agents to Reduce Donor Specific Antibodies, Improve Transplant Rates and Outcomes in Highly-HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
Study Start Date : September 2013
Actual Primary Completion Date : July 28, 2017
Actual Study Completion Date : July 28, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Rituximab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Rituxan
All study patients will receive Rituxan 1g on day 15 from start of desensitization and either 3M or 6M post transplant depending on the presence of DSA.
Biological: Rituxan
Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.
Other Name: Rituximab

Primary Outcome Measures :
  1. Rates of transplantation [ Time Frame: 9 month ]
    This trial is designed to determine if Rituximab + IVIG can improve rates of transplantation for highly-HLA sensitized DD candidates on the UNOS waiting list over a 9M period of time after completion of treatment.

Secondary Outcome Measures :
  1. Renal allograft survival [ Time Frame: 12 months ]
    Graft survival in study participants

  2. Reduction in anti-HLA antibodies [ Time Frame: 9 months ]
    Antibody measurements at multiple time points

  3. Incidence of acute rejection episodes [ Time Frame: 12 months ]
    Number of rejection episodes in study participants

  4. Incidence of serious infections [ Time Frame: 12 months ]
    Infection rate in study participants

  5. Adverse events, toxicity assessments [ Time Frame: 12 months ]
    Adverse effects in study participants

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. End-stage renal disease.
  2. No known contraindications for therapy with IGIV10%/Rituximab.
  3. Age 18-70 years at the time of screening.
  4. PRA> 30% demonstrated on 3 consecutive samples, UNOS wait time sufficient to allow DD offers, history of sensitizing events, positive crossmatch with the intended donor.
  5. Subject/Parent/Guardian must be able to understand and provide informed consent.

Exclusion Criteria:

  1. Lactating or pregnant females.
  2. Pediatric patients <18 years of age
  3. Women of child-bearing age who are not willing or able to practice FDA-approved forms of contraception.
  4. HIV-positive subjects.
  5. Subjects who test positive for HBV infection [positive HBVsAg, HBVcAg, or HBVeAg/DNA] or HCV infection [positive Anti-HCV (EIA) and confirmatory HCV RIBA].
  6. Subjects with active TB.
  7. Subjects with selective IgA deficiency, those who have known anti-IgA antibodies, and those with a history of anaphylaxis or severe systemic responses to any part of the clinical trial material.
  8. Subjects who have received or for whom multiple organ transplants are planned.
  9. Recent recipients of any licensed or investigational live attenuated vaccine(s) within two months of the screening visit (including but not limited to any of the following:

    • Adenovirus [Adenovirus vaccine live oral type 7]
    • Varicella [Varivax]
    • Hepatitis A [VAQTA]
    • Rotavirus [Rotashield]
    • Yellow fever [Y-F-Vax]
    • Measles and mumps [Measles and mumps virus vaccine live]
    • Measles, mumps, and rubella vaccine [M-M-R-II]
    • Sabin oral polio vaccine
    • Rabies vaccines [IMOVAX Rabies I.D., RabAvert])
  10. A significantly abnormal general serum screening lab result defined as a WBC < 3.0 X 103/ml, a Hgb < 8.0 g/dL, a platelet count < 100 X 103/ml, , an SGOT > 5X upper limit of normal, and an SGPT >5X upper limit of normal range.
  11. Individuals deemed unable to comply with the protocol.
  12. Subjects with active CMV or EBV infection as defined by CMV-specific serology (IgG or IgM) and confirmed by quantitative PCR with or without a compatible illness.
  13. Subjects with a known history of previous myocardial infarction within one year of screening.
  14. Subjects with a history of clinically significant thrombotic episodes, and subjects with active peripheral vascular disease.
  15. Use of investigational agents within 4 weeks of participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01178216

United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Sponsors and Collaborators
Stanley Jordan, MD
Genentech, Inc.
Principal Investigator: Stanley Jordan, MD Cedars-Sinai Medical Center

Additional Information:
Responsible Party: Stanley Jordan, MD, Medical Director, Medical Director, Renal Transplantation & Transplant Immunotherpay, Cedars-Sinai Medical Center Identifier: NCT01178216     History of Changes
Other Study ID Numbers: Genentech-Ritux2010
First Posted: August 10, 2010    Key Record Dates
Last Update Posted: December 27, 2017
Last Verified: December 2017

Keywords provided by Stanley Jordan, MD, Cedars-Sinai Medical Center:
Kidney transplant
highly sensitized

Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Diseases
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Urologic Diseases
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents